US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...